Cargando…

Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer

We investigated the association between TP53 mutation and 21-gene recurrence score (RS) in ER-positive/HER2-negative breast cancer (BC) using data from 141 patients who underwent TP53 sequencing and Oncotype DX(®) tests. We detected TP53 mutations in 18 (12.8%) patients. Most patients with TP53 muta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Jung Hwan, Bae, Soong June, Kim, Kyungsoo, Chu, Chihhao, Lee, Kyung-A, Kim, Yoonjung, Kim, Jee Hung, Jeong, Joon, Ahn, Sung Gwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850427/ https://www.ncbi.nlm.nih.gov/pubmed/35173185 http://dx.doi.org/10.1038/s41523-022-00384-3

Ejemplares similares

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
por: Park, Inho, et al.
Publicado: (2023)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor–Positive, ERBB2–Negative Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2022)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
por: Baek, Seung Ho, et al.
Publicado: (2022)

Radiation dose-event relationship after intraoperative radiotherapy as a boost in patients with breast cancer
por: Cho, Yeona, et al.
Publicado: (2023)

Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2023)

Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996)

Clinical Features of Breast Cancer in South Korean Patients with Germline TP53 Gene Mutations
por: Alyami, Hassan, et al.
Publicado: (2021)

Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence After Breast Conserving Surgery With Sentinel Lymph Node Biopsy: Pooled Analysis Using Data From a Systematic Review and Two Institutions
por: Yoon, Chang Ik, et al.
Publicado: (2020)

Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery
por: Yoon, Chang Ik, et al.
Publicado: (2023)

The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2020)

Author Correction: Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2021)

Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Bae, Soong June, et al.
Publicado: (2022)

The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy
por: Lee, Janghee, et al.
Publicado: (2021)

Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score
por: Ahn, Sung Gwe, et al.
Publicado: (2013)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
por: Choi, Hyungwook, et al.
Publicado: (2023)

Complications Including Capsular Contracture in Direct-to-Implant Breast Reconstruction With Textured Anatomical Versus Smooth Round Implants: A Single Center Retrospective Analysis
por: Jeon, Hong Bae, et al.
Publicado: (2023)

Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review
por: Yang, Seongwoo, et al.
Publicado: (2023)

Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients
por: Ko, Sung Min, et al.
Publicado: (2021)

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer
por: Lee, Yangkyu, et al.
Publicado: (2022)

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
por: Andersen, TI, et al.
Publicado: (2000)

TP53 mutations among molecular subtypes of HER2-positive tumors
por: Helland, Å, et al.
Publicado: (2005)

Comparison of complications according to incision types in nipple-sparing mastectomy and immediate reconstruction
por: Park, Soeun, et al.
Publicado: (2020)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Relationship of the standard uptake value of (18)F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
por: Park, Soeun, et al.
Publicado: (2021)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
por: Bae, Soong June, et al.
Publicado: (2020)

Optimal treatment strategy for hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer patients with 1–2 suspicious axillary lymph node metastases on breast magnetic resonance imaging: upfront surgery vs. neoadjuvant chemotherapy
por: Lee, Seung Eun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d0ke6ctbaum6565sd6cj2hih3h